Abstract
A loading dose of MPA employing a regimen of 1,000 mg six hourly for 8 doses can achieve plateau levels above 100 ng ml-1 within the first 36 h of treatment, without any untoward toxicity. This raises the possibility of shortening the time to response for this agent. The additional factor of the time required to achieve adequate serum levels may explain the apparent contradictions between reports correlating response rates and dose and those correlating serum level and response.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blossey H. C., Bartsch H. H., Kanne D., Koebberling J., Nagel G. A. The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer. Cancer Chemother Pharmacol. 1982;8(1):77–81. doi: 10.1007/BF00292875. [DOI] [PubMed] [Google Scholar]
- Cavalli F., Goldhirsch A., Jungi F., Martz G., MermillodB, Alberto P. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol. 1984 May;2(5):414–419. doi: 10.1200/JCO.1984.2.5.414. [DOI] [PubMed] [Google Scholar]
- Cuna G. R., Calciati A., Strada M. R., Bumma C., Campio L. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori. 1978 Apr 30;64(2):143–149. doi: 10.1177/030089167806400204. [DOI] [PubMed] [Google Scholar]
- Johnson J. R., Priestman T. J., Fotherby K., Kelly K. A., Priestman S. G. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer. Br J Cancer. 1984 Sep;50(3):363–366. doi: 10.1038/bjc.1984.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Løber J., Mouridsen H. T., Salimtschik M., Johansson E. Pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular route. Acta Obstet Gynecol Scand Suppl. 1981;101:71–74. doi: 10.3109/00016348109157816. [DOI] [PubMed] [Google Scholar]
- Pannuti F., Camaggi C. M., Strocchi E., Giovannini M., Di Marco A. R., Costanti B. Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients. Cancer Treat Rep. 1982 Dec;66(12):2043–2049. [PubMed] [Google Scholar]
- Pannuti F., Martoni A., Lenaz G. R., Piana E., Nanni P. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Cancer Treat Rep. 1978 Apr;62(4):499–504. [PubMed] [Google Scholar]
- Salimtschik M., Mouridsen H. T., Loeber J., Johansson E. Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes. Cancer Chemother Pharmacol. 1980;4(4):267–269. doi: 10.1007/BF00255272. [DOI] [PubMed] [Google Scholar]
- Shrimanker K., Saxena B. N., Fotherby K. A radioimmunoassay for serum medroxyprogesterone acetate. J Steroid Biochem. 1978 Apr;9(4):359–363. doi: 10.1016/0022-4731(78)90631-3. [DOI] [PubMed] [Google Scholar]